- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07940543
Construction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging
A Study on the Construction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging and Its Prognostic Evaluation Value
Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intra- and extrahepatic bile ducts. Although Kasai portoenterostomy can restore bile drainage, more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction but a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on serum liver function tests and semi-quantitative histological scoring, which cannot reveal the overall metabolic landscape or spatial heterogeneity of the liver. Raman imaging is a label-free, high-spatial-resolution molecular vibrational imaging technique that can simultaneously detect lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products. It has demonstrated metabolic phenotyping capability in tumor heterogeneity, organ development, and nonalcoholic fatty liver disease. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and metabolic boundaries of fibrous septa-remains unexplored by conventional metabolomics. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming that forms characteristic Raman-capturable metabolic signatures, which may serve as novel tools for disease stratification and prognosis prediction. This study aims to construct a Raman-based liver metabolic atlas and evaluate its prognostic value.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intrahepatic and extrahepatic bile ducts. Kasai portoenterostomy can temporarily restore bile drainage, but more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction; it is a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on conventional serum liver function indices (ALT, AST, GGT, TBIL, DBIL, and TBA) and semi-quantitative histopathological scoring. These approaches cannot reveal the overall metabolic landscape or the spatial heterogeneity of the liver, resulting in a lack of systematic understanding of metabolic reprogramming in BA.
Raman imaging is a label-free molecular vibrational spectroscopic imaging technique based on inelastic scattering. It can simultaneously detect chemical bond information from lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products without exogenous probes or labels, and it offers high spatial resolution and non-destructive detection. Raman imaging has demonstrated metabolic phenotyping capability in tumor metabolic heterogeneity, organ development, and nonalcoholic fatty liver disease. Previous studies suggest that BA patients have multiple metabolic abnormalities, including bile acid metabolic disorders. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and the metabolic boundaries of fibrous septa-cannot be obtained by conventional metabolomics, representing an important research gap. Raman imaging has the unique advantage of "spatial metabolomics," enabling metabolic information to be localized to specific pathological structures and providing a new dimension for understanding the relationship between intrahepatic metabolic heterogeneity and disease progression. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming during pathological progression, forming characteristic Raman-capturable metabolic signatures that can comprehensively quantify multidimensional metabolic features and serve as novel tools for disease stratification and prognosis prediction.
Briefly, this single-center prospective observational study will enroll 60 infants with BA undergoing Kasai portoenterostomy and 20 age-matched controls (10 choledochal cysts and 10 intrahepatic cholestasis without BA). Intraoperative liver tissues will be collected and analyzed by confocal Raman imaging with near-infrared excitation and large-area multi-region scanning. HE and Masson staining and image registration will link spectral pixels to histological structures. A full-spectrum database will be established, and spectral unmixing will generate spatial metabolic heat maps, regional metabolic fingerprints, and metabolic gradients. Raman-derived parameters will be integrated with clinical and pathological data to develop a metabolic classification and a prognostic model for native liver survival using Cox and LASSO regression. Participants will be followed for at least 3 years. Primary outcomes are jaundice clearance and native liver survival after Kasai surgery; secondary outcomes include postoperative biochemical indices and liver stiffness. The study poses minimal risk, involves no new drugs or devices, and will be conducted with informed consent and ethical approval.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Zequan Ding
- Telefonní číslo: +8613057659508
- E-mail: dingzqcn@163.com
Studijní místa
-
-
-
Nnajing, Čína
- Nanjing Children's Hospital
-
Kontakt:
- Zequan Ding
- Telefonní číslo: +86 13057659508
- E-mail: dingzqcn@163.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Patients with biliary atresia and undergoing Kasai surgery.
Popis
Inclusion Criteria:
- 1. Obtain the informed consent from the parents of the patients; 2. Children diagnosed with biliary atresia and undergoing Kasai surgery; 3. The control group consists of children with age-matched choledochal cysts and those with intrahepatic cholestasis excluding biliary atresia; 4. The medical records are complete.
Exclusion Criteria:
- 1. Without obtaining the informed consent of the parents; 2. Children diagnosed with biliary atresia through cholangiography but not undergoing the Kasai surgery; 3. Children with incomplete medical records.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Biliary atresia
Biliary atresia patients who undergo Kasai surgery |
All the intraoperative liver biopsy tissues of the participants will undergo Raman imaging to assess the metabolic status of the liver tissues. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Juandice clearance
Časové okno: 3 months post Kasai augery
|
Serum direct bilirubin < 2mg/dL |
3 months post Kasai augery
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Native liver survival
Časové okno: 2 years post Kasai augery
|
Native liver survival without liver transplantation or death |
2 years post Kasai augery
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- NCH202608045-1
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
De-identified individual participant data (including demographic, clinical, and outcome variables) collected during the trial will be made available to qualified researchers.
Časový rámec sdílení IPD
Data will become accessible:Starting Date: 6 months after study completion;End Date: Minimum 5 years after publication.
Kritéria přístupu pro sdílení IPD
Access to IPD requires submitting a formal research proposal (including hypothesis/analysis plan, ethical approval proof if applicable, and conflict of interest disclosure) to the investigator's email, along with a signed Data Use Agreement (DUA) prohibiting re-identification, commercial use, and redistribution.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- ANALYTIC_CODE
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .